brain has been described in several case reports, challenging the concept that these malformations are static entities. 18, 24, 27, 47, 64, 72, 75, 76, 80, 81, 85, 86, 90, 112, 116, 118 One series of 106 patients with AVMs has demonstrated that > 50% of the lesions increased in size, whereas 9% decreased over a mean period of 8 years without intervention. Remodeling within these lesions can lead to changes in their angiographic appearance over time.
To appreciate why these changes occur, it is necessary to review the different forces acting on the growth and behavior of individual AVMs. These forces begin during vasculogenesis and angiogenesis in the fetal brain, when a number of cellular behaviors (apoptosis, migration, differentiation, and proliferation) affect the potential development of vascular lesions. The embryology relevant to vascular development will be reviewed in this paper, and the molecular factors, including growth factors and extracellular proteins, will be explored. Finally, we consider the relevant physiology and vascular architecture in reference to the behavior of brain AVMs.
Vasculogenesis and Angiogenesis
The vascular and nervous systems are the 2 earliest developing organs in vertebrates. There are 2 neuronal cerebral cortical migrating populations: radial and tangential. Cerebral cortical vascular development has 2 components-a ventriculopetal (most abundant) and a ventriculofugal (least abundant). Both components develop along and parallel to the radial neurogenesis. The cellular titer of the VEGF family within the ventricular zone is high during the early period of corticogenesis. It is a key factor in the migration of the centripetally directed vessels. The molecular environment is critical to cell fate and vascular development (Figs. 1A and B and 2).
There are 2 phases to vascular development: vasculogenesis and angiogenesis. Vasculogenesis is the formation of primitive endothelial cells (VEGF is the earliest vascular marker). Angiogenesis is defined by morphogenic changes hallmarked by ongoing "pruning" of the premature vascular plexus, the formation of new branches, and stabilization of the definitive vessel. Over the past 2 decades, an accumulating body of information has demonstrated some of the chemical and molecular factors critical to vasculogenesis and angiogenesis (Table 1) . 104 The progenitor cells destined to evolve into angioblastic cells can be modulated by FGF. The roles of HIF and sonic hedgehog are suspected of influencing the induction of these vascular progenitor cells that become endothelial and hematopoietic cells. The hemangioblastic progenitor cells clump together and are the earliest cells to express Generally the radial glia and radial neuronal migration are perpendicular to the tangent of the cortical surface. The radial neuronal migration projects from the ventricular surface of the cortical mantle to the pia marginal layer. The tangential neuronal migration from the ganglionic eminence of the striatum moves parallel to the cortical surface and is unassociated with any significant counterpoint vascular development. The cerebral cortical vascular development has 2 components: a ventriculopetal (most abundant) and a ventriculofugal (least abundant). Both develop along and parallel to the radial neurogenesis. Thus, the early cerebral vascular system and cortical glial/neuronal development of the ventricular, subventricular, subcortical plate, and cortical plate zones progress through morphogenesis predominantly in a parallel anatomical fashion. The cellular titers of the VEGF family within the ventricular zone are high during the early period of corticogenesis, which is a key factor in the migration of the centripetally directed vessels. B: Gross depiction of the early cerebral vascular and neural system in the embryo.
VEGF-A ligands and VEGFR-2. These angioblastic cells can form angiocysts, which then migrate and ultimately fuse forming a primitive capillary plexus. This complex of an immature VEGF/VEGFR-positive vascular plexus defines the end of vasculogenesis and a downregulation of VEGF. The foundation for specific regions of new branching or pruning of primitive plexus radicals, caused by apoptosis, emerges. This pruning of the vessels marks the transition to angiogenesis.
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The primitive capillary plexus has 3 basic characteristics. The surrounding mesenchymal cells migrate around the primitive capillary plexus and differentiate into SMCs and pericytes. As noted, there is programmed cell death to specific regions of the primitive capillary plexus, causing a remodeling of the vascular architecture. Finally, new branches form, and stabilization of the mature vascular structure occurs. The molecular aspects of vasculogenesis and angiogenesis are complex; however, aberrations of molecular signaling can lead to abnormal vascular development.
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Normal embryogenesis requires the timely expression of a balance between anti-and proapoptosis, cell attraction and repulsion, cell migration and cell fixation, and cell proliferation and cell differentiation. For endothelial cells to enter regions of organogenesis, the activation of migration, branching, and proliferation factors as well as substrates is required. However, differentiation into more stable and mature vascular elements cannot occur during the proliferation phase. Thus, downregulation of the complex processes responsible for these events must occur. The subsequent upregulation of factors influencing differentiation and maturation is eventually required to become the key and major players. The magnitude and complexities of growth factors, morphogens, and cytokines; the critical timelines of upregulation and downregulation; and the spectrum of isoforms in any given family of activators or inhibitors is just beginning to be understood in vasculogenesis and angiogenesis.
Molecular Biology of AVMs: VEGF, TGFβ, and ANGs
The altered expression of up to 900 genes has been associated with AVMs. 73 Perhaps > 300 genes are upregulated and almost 560 are downregulated in cerebral vascular malformations. 111 These genes encode growth factors, cell adhesion and ECM factors, inflammatory factors, MMPs, and endocrine hormones. Different cell types, including endothelial cells, vascular SMCs, and inflammatory cells, have been examined to understand the pathogenesis of AVMs. Tables 1-3 summarize several molecular factors involved in vascular development and their role in AVMs.
Vascular endothelial growth factors consist of 6 subtypes labeled VEGF-A to VEGF-E and placental growth factors. The main isoform is VEGF-A. Furthermore, each subtype can have several splice variants. 56, 73, 83, 92 Vascular endothelial growth factor-A is expressed in astroglia adjacent to AVMs, whereas VEGF-C and -D expression is higher in malformations with larger niduses. Moreover, VEGF-C and -D may also contribute to AVM growth.
62
All VEGF subtypes and their variants bind vascular endothelial tyrosine kinases (VEGFRs). Specific receptors include Flt-1 (VEGFR-1) and KDR (Flk-1 or VEGFR-2). On ligand binding, the activated pathway leads to the replication, migration, differentiation, and survival of endothelial cells (Figs. 3-5 ).
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Vascular endothelial growth factor is a soluble factor that has a potent mitogenic effect on vascular endothelial cells in large and small vessels both in vivo and in vitro. 10, 60, 96 Notably, the development of the embryonic vascular system is highly dependent on the actions of soluble factors. 10, 51, 52, 84, 94, 95, 101, 137 Vascular endothelial growth factor is expressed at high levels during embryonic development, but its expression is normally suppressed in the adult cerebral vasculature. 114 Interestingly, VEGF is highly expressed in children with recurrent cerebral AVMs.
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The expression of VEGF is high in the endothelial layer and media of vessels in AVMs. 105 Pathological studies have shown that almost three-quarters of AVMs resected following incomplete embolization express VEGF and Flk-1, whereas the endothelium of only one-quarter of AVMs not preoperatively embolized expresses these factors. 121 This finding may explain why partially obliterated AVMs recur.
Vascular endothelial growth factor receptors, normally expressed only by endothelial cells of the blood vessels and vascular wall SMCs, may play a pivotal role. 62, 121 The increased expression of the Flt-1, Flt-4, and Flk-1 receptor subtypes occurs around AVMs. The Flk-1 epitope is significantly expressed in the endothelium of the AVM nidus. Interestingly, Flk-1, the receptor for VEGF-D, is normally expressed only by the vascular endothelium of the developing fetal brain. 121 The fact that AVMs express embryological substrates implies that the formation of these lesions is an active process, beginning in utero and continuing into childhood.
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The roles of the TGF family in vascular development are complex and multidimensional; for example, TGFβ is biphasic. In the early stages of development, TGFβ inhibits vascular endothelial proliferation; in later stages, it promotes the differentiation of surrounding mesenchymal cells to differentiate into pericytes and SMCs. With the influence of PDGF, ANG, and TIE receptors, these cells encircle the primitive vascular plexus endothelium as part of angiogenesis.
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Transforming growth factor-β activates the dimerization of a Type I or II receptor that initiates the activation of multiple cytoplasmic and nuclear factors. 79 The ENG gene, encoding for proteins in the TGFβ1 receptor complex, is mutated in hereditary hemorrhagic telangiectasia. Cerebral AVMs are found in up to 10-25% of patients with this genetic disorder. 99 The ENG mutation is associated with a higher prevalence of cerebral AVMs.
6,19
An important downstream cofactor, endoglin, enhances ALK1 effects on endothelial proliferation. Mutations of endoglin and/or ALK1 can result in vascular abnormalities such as hereditary hemorrhagic telangiectasia and arteriovenous fistulas. 69, 130 The failure of ALK5/endoglin, which normally enhances endothelial development, may lead to a deficiency in the capillary plexus maturation bridging the arteriovenous interval, which results in arteriovenous fistula development. The ALK5 activation may modulate the endothelial cellular inhibition of proliferation and migration. Transforming growth factor-β plays a complex role in angiogenesis, and the effects of its downstream substrates may be critical in de novo AVM formation (Figs. 6-8) .
Angiopoietins regulate the recruitment of pericytes and smooth muscle precursors and are involved in angiogenesis and vascular stability. More specifically, ANG-1 uses an endothelial cell-specific tyrosine kinase (TIE2, or TEK), whereas ANG-2 is a TIE2 antagonist. Angiopoietin 1 promotes interactions between endothelial and support cells to stabilize vessels, whereas ANG-2 is a deconstructive signal that promotes vascular remodeling or destabilization. 53, 108, 125 Although downregulated in the mature quiescent vasculature, ANG-2 expression is upregulated in brain AVMs. 41 Phenotypes observed in vivo because of the overexpression of ANG-2 are similar to brain AVM vessels, with abnormally dilated vessels that lack a mature periextracellular support structure.
77 Furthermore, TIE2 has upregulated autophosphorylation in AVMs (Fig. 9) . 5 This gene has been found to be mutated in the systemic familial venous malformation syndrome, which has many similarities to AVMs.
128 Angiopoietin 1 protein levels are 30% lower, ANG-2 protein levels are 800% higher, and ANG-2 mRNA levels are 40% higher in brains with AVMs compared with controls.
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The growth potential of AVMs and their regression may involve opposing forces supporting or inhibiting angiogenesis and vascular remodeling. A phenomenon noted in tumor angiogenesis is the need for both VEGF and ANG-2; if VEGF is absent, vessels will undergo regression if ANG-2 is present. 77 Furthermore, the 2 opposing actions of the ANGs, ANG-1 and ANG-2, can actually change depending on vessel size and concentration levels. For example, ANG-2 at high concentrations can actually switch from an antagonist to agonist for the TIE2 receptor. 59 In general, ANG-1 and ANG-2 appear to have opposing effects: one aids the development of a structurally sound vascular network, while the other creates a disorganized and defective network.
Hyperangiogenic Environment
The hypoxic environment surrounding the brain AVM is thought to stimulate the secretion of all the aforementioned angiogenic factors and their levels of activity. It is known that both hypoxia and ischemia lead to the secretion of VEGF, its receptors, and other growth factors. 71, 119 Astrocytes have been shown to secrete VEGF when exposed to a hypoxic environment. The VEGF gene promoter contains a response element called HIF-1, which can increase VEGF expression 30-fold within minutes of being exposed to hypoxic conditions (Fig.  10) . 4, 36, 38, 113 This hypoxic environment may be induced by arteriovenous shunting through the AVM.
Several studies have supported the idea of hypoxic/ ischemic angiogenic stimulation in brain AVMs. Vascular endothelial growth factor and HIF are expressed in a much higher percentage of embolized AVMs compared with emergently surgically treated malformations, alluding to hypoxic stimulation of VEGF within the local AVM environment. In cases of partial embolization (or occlusion), local endothelial hypoxia can result within the obliterated portion of the AVM nidus. 121 This hypoxic condition may 4 . Schematic demonstrating the VEFG-A ligand initiating a homodimerization of VEGFR-2. This activates receptor kinases and autophosphorylation of tyrosines on the cytodomain portion of the VEGFR-2, which activates a series of cytoplasmic and membrane-bound substrates (Grb, Ras, Raf, and MAPK). The phosphorylation of MAPK initiates entry into the nucleus and the activation of transcription factors for endothelial proliferation, endothelial survival, endothelial fenestration/permeability, and development of primitive capillary plexuses. Note that PAL-E is present in nonbarrier vessels and absent in barrier vasculature elements such as the brain (blood-brain barrier) and retinal vessels (retinal blood barrier). With the overexpression of VEGF-2, PAL-2 endothelial marker increases with an associated capillary permeability. Neuropilin-1/neuropilin-2 are obligate coreceptors that enhance VEGF-A/VEGFR-2. In contrast, VEGFR-1 has some inhibitory effect on VEGFR-2. mediate neovascularization and underscores the need for complete obliteration of the nidus. Note, however, that VEGF and HIF can also be upregulated independently of embolization, indicating other mechanisms at work.
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It is also important to consider that while the environment surrounding the brain AVM may be facing an ischemic/hypoxic insult, the nidus is actually well perfused with arterial blood at high flow rates. Since the nidus does not generally contain any neuronal tissue and thus has little potential to become ischemic, factors affecting the growth or regression of the nidus may be different from those that affect the surrounding vessels. It is also possible that microhemorrhage or frank hemorrhage act as a stimulus for angiogenesis. In a process described as "hemorrhagic angiogenic proliferation," certain blood factors, such as hemosiderin, fibrin, and fibrin split products, are known (experimentally) to stimulate vascular growth.
3,17,132

Structural Proteins and the ECM
Integrins, immunoglobulins, cadherins, and selectins, along with the ECM milieu, may have significant effects on angiogenesis, vasculogenesis, and brain AVM growth. Arteriovenous malformations in the brain exhibit a mature vessel wall phenotype, as evidenced by intense laminin expression localized in and around the internal elastic lamina and the absence of significant fibronectin expression. 58, 105 Fibronectin and laminin are found in basement membranes of normal vascular beds, providing structural support to the vessel wall by anchoring endothelial cells to the underlying internal elastic membrane and smooth muscle layers. The relative ratio of laminin to fibronectin expression provides a partial indicator of vessel wall maturity. Immature vessels are associated with a fibronectin-rich matrix deficient in laminin. Mature vessels express laminin more consistently and contain little to no fibronectin in their matrix. 23, 32, 61, 65, 82, 87, 102 The presence of laminin in AVMs probably contributes to the resilience of these vessels in the face of hemorrhage compared with CMs (immature vessels), which are prone to repetitive microhemorrhages.
61,65
Integrins, a superfamily of receptors, are anchored to the ECM and transduce signals from the extracellular environment to the cell's interior. 13, 49, 50, 106 At least 16 distinct α and 8 distinct β integrin subunits have been identified as having the ability to regulate a variety of cellular responses, including adhesion, migration, invasion, proliferation, cell survival, and apoptosis (Fig. 11) . 11, 12, 34, 35 Integrins are required for the optimal activation of growth factor receptors including VEGF and bFGF-2 factors important in the growth of brain AVMs. 2, 12, 15, 20, 28, 51, 52 The ligand-receptor interaction in these pathways becomes optimal only under appropriate conditions for cell attachment, a process strictly regulated by integrins. 11, 20, 34, 35 Both integrin a v β 1 and α v β 3 are strongly associated with AVMs. 74, 109 Integrin α v β 1 is an important regulator of angiogenesis from the early/immature phases to the late maturation phases, whereas α v β 3 is mainly responsible for coordinating the early stages of angiogenesis. 11, 12, 28, 109 The expression of α v β 1 has been shown to be greater in brain Schematic showing processes associated with TIE2. The TIE2 receptor protein kinase is activated by ligand ANG-1 and inhibited by ANG-2. Activation of this endothelial protein tyrosine kinase receptor possibly activates the transcription of PDGF, EGF, and VEGF. This activates mesenchymal cells to migrate toward the primitive endothelial vessel and also elaborates ANG isoforms. Transforming growth factor-β is also secreted by mesenchymal cells and in early embryogenesis inhibits endothelial proliferation. Moreover, in an autocrine manner mesenchyma participates in its differentiation into SMCs and pericytes. In TIE2-null animals (−/−) in the presence of VEGF-A/VEGFR-2, there is the formation of large blood vessels with fewer branches, clumping of the endothelial cells, and loss of supporting cells approximating to the endothelial cells. The same is observed with ANG-1 ligand−null animals. Angiopoietin-2 also binds with TIE2 with high affinity but does not activate the tyrosine kinase receptor; however, it inactivates the receptor and blocks its availability to ANG-1 ligand. If ANG is transgenically overexpressed, it will yield a phenotype equivalent to an ANG-1−null animal. This complex relationship of ANG-1 and -2 with TIE receptors can be related to angiogenic defects and brain AVMs.
AVMs compared with that in CMs specifically in the endothelium, subendothelium, and media. 109 The α v β 3 subtype is expressed in both brain AVMs and CMs. 132, 133 The α v β 3 antagonists, potential pharmacological agents in the treatment of AVMs, have a minimal effect on preexisting blood vessels 13, 14, 16 and are limited in cellular distribution. They are completely absent in epithelial cells, which are usually nonspecifically targeted with other drugs.
9,66
Matrix metalloproteinases, specifically MMP-9, may play a key role in brain AVM growth and spontaneous hemorrhage by affecting vascular stability and angiogenesis as they degrade pericellular substrates. 120 In murine models of abdominal aortic aneurysms, targeted deletions of the MMP9 gene specifically suppress experimental aneurysm formation. 100 Furthermore, MMP-9 is increased relative to tissue inhibitors of metalloproteinases (TIMP-1, -3, and -4) in brain AVMs.
43 Follow-up experiments have shown that tetracyclines (doxycycline and minocycline) have a dose-response relationship for inhibiting stimulated cerebral MMP activity. 70 Tetracyclines may have a future role in supporting the vascular stability of these lesions.
Cell Types
Endothelial cells play a fundamental role in vasculogenesis, angiogenesis, and vascular remodeling. Postnatally, endothelial cells are quiescent but possess proliferative potential. Studies using Ki 67 (or MIB-1) and proliferating cell nuclear antigen have demonstrated that brain AVMs have a significantly higher rate of endothelial cell turnover compared with that in control vessels, suggesting the presence of active angiogenesis and/or vascular remodeling in these lesions. 42, 44, 121 Hashimoto et al.
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have concluded that the rate of endothelial cell turnover in brain AVMs is somewhere between that of normal quiescent cerebrovascular endothelial cells and endothelial cells in progressing tumors. Vascular SMCs also play an essential role in vessel maturation during vasculogenesis and angiogenesis. The pathogenesis of AVMs partly involves the abnormal assembly or differentiation of vascular SMCs, which have the unique potential to differentiate into various stages of maturity with each stage characterized by the unique expression of phenotypic markers.
127 Specifically, the varied expression of 3 types of proteins-α-SMA, myosin heavy chains (including the isoforms that result from alternative splicing of mRNA, SM1, and SM2, and 2 other isoforms, SMemb, and NMHC-A), and a recently identified cytoskeletal protein called smoothelin-leads to a range of vascular smooth muscle morphology. The α-SMA is Fig. 10 . Schematic demonstrating steps in hypoxia and normoxia. Given that there is no vascularity in the developing embryo, the relative hypoxia of the peripheral embryonic disc may induce HIF-1a, which increases VEGF and other factors. In an environment with normal oxygen tension, the 2 proline amine acids on the HIF-1a molecule are available to be hydroxylated by a specific proline hydroxylase. The conversion of HIF-1a proline to hydroxyproline makes it susceptible to complex with a VHL (Von Hippel-Lindau tumor suppressor protein). A trimeric moiety with HIF-1a hydroxyproline is formed and enters polyubiquitylation and ultimately undergoes degradation in the proteosome. In contrast, in a hypoxic environment, the HIF-1a escapes vulnerability to proteosomic degradation. It will complex with HIF-1b, which is permeable to the nuclear membrane, and then translocate into the nucleus. It acts as a transcription factor for VEGF. It also enhances the transcription of PDGF, TGF, Notch, Oct4 (stimulates stem cell proliferation), and Cyclin D (activates mitosis via cell entry into G-1 and S-phase of the cell cycle). Thus, a low oxygen tension environment increases provasculogenic substrates.
expressed in all stages of vascular SMC differentiation, whereas myosin heavy chains are expressed in only the later stages; within the family of myosin heavy chains, SM2 is expressed later than SM1. Smoothelin is found predominantly in the mature SMCs and provides the contractile properties. 21, 88, 98, 127 In brain AVMs embedded in paraffin tissue, smoothelin expression is significantly decreased in the large vessels. 126 In cells cultured from brain AVMs, smoothelin was absent. The absence of smoothelin in AVMs is thought to reflect the disappearance of contractile properties resulting from the hemodynamic stress that these lesions encounter. The venous components of cerebral AVMs, on the other hand, show prominent expression of α-SMA and myosin, reflecting their new "arterialization." 47, 48, 126 The level of these proteins (especially smoothelin) may influence AVM rupture rates.
Recently, the role of MAPK pathways in the vascular SMCs of brain AVMs has been elucidated. The MAPKs are a family of serine/threonine kinases that are highly conserved and ubiquitously expressed in response to a variety of stimuli. Specifically, ERKs, members of this MAPK family, may help to explain brain AVM dynamics. Previous studies have shown that ERKs are activated in response to growth factors, oxidative stress, increases in intracellular calcium levels, and/or glutamate receptor stimulation. 1, 8, 25, 89 After stimulation, ERK induces cellular proliferation and transformation. 25, 89, 110, 134 Takagi and colleagues 124 have suggested that the activation of the ERK pathway depends on the chronic increase in blood flow within the vasculature. It has been well established that chronic increases in blood flow can upregulate shear-induced genes, which induce vascular remodeling. 143 In brain AVMs, intranidal vessels are exposed to abnormally high blood flow that creates high shearing forces, which can similarly activate shearinduced genes. 40 Takagi and colleagues have shown that phosphorylated ERK is upregulated in the SMCs of the media layer in brain AVMs. The activation of this pathway signals SMC proliferation, which contributes to the vascular remodeling and growth/regression of these lesions.
The role of inflammatory cells in brain AVMs was considered as early as 1949, when Sorgo 115 hypothesized that the combination of "circulatory factors and perivascular leukocytes" might stimulate the growth of vessels in these lesions. An inflammatory cell infiltrate is present in both ruptured and unruptured cerebral AVMs.
26,33 After hemorrhage, the inflammatory response in the brain includes persistent infiltration of macrophage/microglia for up to 4 weeks. 37 These inflammatory cells have been found in and around AVM vessel walls as well as in surrounding brain parenchyma. It is conceivable that the presence of inflammatory cells in or around AVM vessels is a gauge for their growth or remodeling.
Interleukin-6, an inflammatory cytokine with a possible role in remodeling the AVM wall, is released by endothelial cells within the AVM nidus. It may contribute to vascular wall instability by stimulating the release of MMP. 22, 29 An identified polymorphism of this interleukin, IL6-174G allele, reportedly increases the risk of intracranial hemorrhage in patients with brain AVMs.
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Apoptosis in Brain AVMs
Apoptosis balances cell proliferation. Possible stimuli activating the proapoptotic pathways in brain AVMs include the following: 1) high local concentrations of oxidants such as oxygen free radicals, NO, and oxidized lowdensity lipoproteins; 2) inflammatory cytokines such as interleukin-1β, tumor necrosis factor-α, and interferon-γ; 3) direct interaction with inflammatory cells, particularly T lymphocytes and macrophages; and 4) hemodynamic stress and changes in perinidal cerebral blood flow.
In situ DNA fragmentation labeling shows evidence of apoptotic activity within and around brain AVMs.
122 Two major apoptotic pathways for AVMs are currently known: the death receptor pathway involving caspase-8, and the mitochondrial pathway involving oxidative stress, the release of cytochrome-C, and the activation of caspase-9. Perinidal neuronal loss around AVMs is associated with Fas-associated death domain proteins and caspase-8.
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The expression of caspase-3, a factor in apoptotic pathways, has been observed in the endothelium, media, and perivascular tissue.
Cells cultured from surgical specimens of brain AVMs demonstrate a proliferation rate 1.8-6.4 times greater than that in human umbilical veins, human arterial endothelial cells, and human microvascular cells. Furthermore, this high proliferation rate was not sensitive to some well-known inhibitory factors such as dexamethasone. 131 Brain AVMs are also associated with the ets-1 protooncogene, and ets-1 has been shown to regulate genes involved in the proliferation and apoptotic processes. The low response to cytokines, the higher propensity to proliferate, and the ets-1 expression all suggest that brain AVMs proliferate because of a dysregulated apoptotic process. Although its role is unclear, dysregulated proliferation/apoptosis within and around brain AVMs may have a part in remodeling these lesions over time.
Conclusions
Because > 900 genes are thought to be involved in the pathogenesis of vascular malformations, elucidating the molecular characteristics of these lesions and their growth patterns has proven to be challenging. 73 Most laboratory work on brain AVMs has been limited to immunohistochemical studies, and thus conclusions have been confined to a biologically inactive system. Dynamic in vivo models, such as lines of endothelial cell cultures and fibrocyte cultures from resected AVMs, are a potential research area. The identification of molecular targets, such as integrins, ANGs, VEGF, HIF, and TGFβ, is critical for targeted drug discovery. The future of endovascular treatment may involve direct infusions of antiangiogenesis agents or embolizations utilizing material coated with antiangiogenic factors.
